Diet, metformin or GLP-1 drug in subtypes of type 2 diabetes
Compares diet, metformin and GLP-1 drugs in prediabetes or diabetes.
Key facts
- Who runs it
- Stanford University
- Where
- Stanford, United StatesSee the site
- Trial code
- Registry title
- Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 200 people, planned
- Started
- Nov 2024
- Expected to end
- Dec 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- Metformin
- GLP-1A
- MED
- Record updated
- 12 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with prediabetes or mild type 2 diabetes who are not taking diabetes medicines. They will test three treatments over time.
- Age
- 18 to 75 years
- Sex
- All sexes can join
- Disease stage
- Prediabetes or mild type 2 diabetes. HbA1c 5.7-8.0% (39–64 mmol/mol) while not on diabetes medicines. BMI ≥23 (≥22 in Asians) but < 45 kg/m2.
- Earlier treatment
- Cannot be taking diabetes, diabetes-causing or weight loss medicines now. A washout is allowed if the primary physician approves.
- Biomarker or test result
- HbA1c 5.7-8.0% (39–64 mmol/mol) while not on antihyperglycemic medications.
Main reasons for not taking part
- Heart or blood vessel event in the last 6 months
- Active cancer, kidney or liver disease, pregnancy or breastfeeding
- History of acute pancreatitis, or medullary thyroid cancer in self or family
- Heavy alcohol use
- Cannot come to the Stanford CTRU for testing
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- BMI ≥23 (≥22 in Asians) kg/m2 but < 45 kg/m2
- HbA1c 5.7-8.0% while not on antihyperglycemic medications
Who cannot take part
- current use of antihyperglycemic, diabetogenic, or weight loss medications (washout allowed if approved by primary physician)
- active malignancy, kidney/liver disease pregnancy/lactation, chronic inflammatory disease, eating disorder, bariatric surgery
- history of acute pancreatitis
- family or personal history of medullary thyroid cancer
- hct <30, creatinine > 1.4, ALT> 3x ULN
- Recent (<6mos) CVD event
- heavy alcohol use
- physical activity >2 hours/day
- inability to come to Stanford CTRU for metabolic testing
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- Stanford UniversityStanford, United StatesContact: Alina Choi, BSNot yet recruiting
About the trial
What the trial wants to find out
The study team will invite participants with prediabetes or mild diabetes (HbA1c 5.7-7.0) to join a 5-year research study that will define subphenotypes of type 2 diabetes based on underlying physiology (eg insulin resistance, beta-cell dysfunction, incretin defect, liver insulin resistance) and then test the hypothesis that response to three first-line treatments will vary according to metabolic subphenotype. Variables of interest include glucose, cardiovascular risk markers, and weight. Treatments include Mediterranean diet, metformin, and a GLP-1 agonist. Participants will go through an initial screening, followed by three treatment periods, each lasting 4 months with 3 month washout in-between treatment periods. This study will help us understand how personalized treatments can help control blood glucose, reduce cardiovascular risk, and manage weight. While there may be minor side effects-like slight discomfort from blood tests, gastrointestinal symptoms from some of the medications, and small radiation exposure from DXA body scans-the treatments offered in this study have all been well studied and are known to lower risk for diabetes and cardiovascular disease
The 3 groups in the trial
- Mediterranean Diet/GLP1a/MetforminTreatment being tested
1. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat. 2. 3 months washout 3. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols. 4. 3 months washout 5. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.
Treatment: Metformin, GLP-1A, and MED
- Metformin/Mediterranean Diet/GLP1aTreatment being tested
1. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week. 2. 3 months washout 3. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat. 4. 3 months washout 5. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.
Treatment: Metformin, GLP-1A, and MED
- GLP1a/Metformin/Mediterranean DietTreatment being tested
1. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols. 2. 3 months washout 3. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week. 4. 3 months washout 5. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.
Treatment: Metformin, GLP-1A, and MED
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
- Plain-language title
- Diet, metformin or GLP-1 drug in subtypes of type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06682351, who can take part
- Record updated
- 12 November 2024